Fig. 7

Correlation between change in IDSIQ total scores and a quality of sleep and b morning sleepiness, as assessed by VAS at Week 12. Scatter plots showing correlation of change from baseline to Week 12 in IDSIQ total score and a change from baseline in quality of sleep assessed by VAS and b change from baseline in VAS morning sleepiness, in patients treated with daridorexant 25 mg, daridorexant 50 mg and placebo. IDSIQ, Insomnia Daytime Symptoms and Impacts Questionnaire; VAS, visual analog scale